GlassScriptPhysician profile
Otakar Na Quadrat
NPI 1245286624
$23,500.91
in general payments reported to CMS, 2019-2025
46 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,049 · 2020: $1,527 · 2021: $3,322 · 2022: $3,079 · 2023: $3,021 · 2024: $2,714 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,396 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,395.52 |
| Education | $127.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $5,393.75 | 2019-2020 | |
| Abiomed | $2,761.01 | 2019-2025 | Impella |
| Janssen Pharmaceuticals, INC | $1,225.40 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,185.54 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,175.16 | 2019-2025 | Farxiga, Brilinta, Andexxa |
| Boston Scientific Corporation | $1,151.74 | 2019-2025 | Watchman Access System, Watchman Flx, Versacross Access Solution |
| Amgen INC. | $1,110.91 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $769.06 | 2021-2025 | Micra, Onyx Frontier, Resolute Onyx |
| Cardiovascular Systems INC. | $747.76 | 2019-2023 | Diamondback Coronary |
| Novo Nordisk INC | $722.61 | 2021-2025 | Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $650.09 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $571.76 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $566.56 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $538.35 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $525.12 | 2021-2025 | Verquvo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $515.85 | 2019-2023 | Onpattro |
| Cvrx, INC. | $502.55 | 2019-2025 | Barostim Neo System |
| Pfizer INC. | $502.19 | 2019-2025 | |
| Amarin Pharma, INC. | $431.71 | 2019-2022 | |
| Abbott Laboratories | $266.32 | 2019-2024 | Amplatzer Amulet, Diamondback Coronary, Confirm Rx |
| Penumbra, INC. | $219.28 | 2023-2024 | Indigo System |
| Bayer Healthcare Pharmaceuticals INC. | $212.15 | 2021-2025 | |
| Kestra Medical Technology Services, INC. | $204.92 | 2025 | Assure Wcd |
| Lilly USA, LLC | $156.07 | 2022-2025 | Zepbound, Mounjaro |
| Shockwave Medical, INC | $148.16 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $141.08 | 2025 | Uptravi, Opsumit, Opsynvi |
| Edwards Lifesciences Corporation | $137.46 | 2021 | |
| Cleerly, INC. | $125.56 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Kiniksa Pharmaceuticals, LTD. | $87.14 | 2021-2023 | Arcalyst |
| Livanova USA, INC. | $83.85 | 2023 | Protekduo |
| Kiniksa Pharmaceuticals International, Plc | $79.87 | 2024 | Arcalyst |
| Philips North America LLC | $71.41 | 2020-2024 | (Ck7) Extended Holter |
| Lexicon Pharmaceuticals, INC. | $64.17 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $56.21 | 2022-2023 | Injectafer |
| Opsens INC. | $54.99 | 2019 | |
| Portola Pharmaceuticals, LLC | $48.50 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $46.18 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $42.41 | 2024 | Optimizer |
| Bardy Diagnostics, INC. | $39.00 | 2019-2021 | |
| United Therapeutics Corporation | $34.27 | 2025 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.53 | 2020-2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $29.16 | 2019 | |
| Lundbeck LLC | $20.95 | 2019 | |
| Cardiva Medical, INC. | $19.84 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Alexion Pharmaceuticals, INC. | $17.61 | 2022 | |
| Irhythm Technologies, INC. | $16.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Otakar Quadrat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.